Monte Rosa Therapeutics

Monte Rosa Therapeutics Net Income

The Net Income of Monte Rosa Therapeutics (GLUE) as of Nov 20, 2026 is -38.63 M USD. In the previous year, Net Income was -72.70 M USD — a change of -46.87% (higher).

Net Income

-38.63 MUSD

YoY

-46.87%

Last updated:

In 2025, Monte Rosa Therapeutics's profit amounted to -38.63 M USD, a -46.87% increase from the -72.70 M USD profit recorded in the previous year.

The Monte Rosa Therapeutics Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-135.35 M USD
Jan 1, 2024
-72.70 M USD
Jan 1, 2025
-38.63 M USD
Jan 1, 2026 (e)
-76.55 M USD
Jan 1, 2027 (e)
-131.60 M USD
Jan 1, 2028 (e)
-118.66 M USD
Jan 1, 2029 (e)
-163.49 M USD
Jan 1, 2030 (e)
-158.97 M USD
The Monte Rosa Therapeutics Net Income history
YEARNet IncomeYoY
est-158.97 MUSD-2.77%
est-163.49 MUSD+37.78%
est-118.66 MUSD-9.83%
est-131.60 MUSD+71.90%
est-76.55 MUSD+98.19%
-38.63 MUSD-46.87%
-72.70 MUSD-46.29%
-135.35 MUSD+24.75%
-108.50 MUSD+46.71%
-73.96 MUSD+106.13%
-35.88 MUSD+347.54%
-8.02 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Monte Rosa Therapeutics Revenue

Monte Rosa Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-143.31 M USD
-135.35 M USD
Jan 1, 2024
75.62 M USD
-81.11 M USD
-72.70 M USD
Jan 1, 2025
123.67 M USD
-54.21 M USD
-38.63 M USD
Jan 1, 2026 (e)
103.14 M USD
-57.83 M USD
-76.55 M USD
Jan 1, 2027 (e)
62.13 M USD
-75.24 M USD
-131.60 M USD
Jan 1, 2028 (e)
120.83 M USD
-159.86 M USD
-118.66 M USD
Jan 1, 2029 (e)
116.07 M USD
-146.95 M USD
-163.49 M USD
Jan 1, 2030 (e)
138.77 M USD
-142.89 M USD
-158.97 M USD

Monte Rosa Therapeutics Margins

Monte Rosa Therapeutics stock margins

The Monte Rosa Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Monte Rosa Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Monte Rosa Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
93.24 %
- %
- %
Jan 1, 2024
89.26 %
-107.26 %
-96.14 %
Jan 1, 2025
93.24 %
-43.83 %
-31.23 %
Jan 1, 2026 (e)
93.24 %
-56.07 %
-74.22 %
Jan 1, 2027 (e)
93.24 %
-121.09 %
-211.80 %
Jan 1, 2028 (e)
93.24 %
-132.30 %
-98.20 %
Jan 1, 2029 (e)
93.24 %
-126.60 %
-140.85 %
Jan 1, 2030 (e)
93.24 %
-102.97 %
-114.56 %

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics, Inc. develops precision medicines using molecular glue degraders (MGDs), small molecule drugs that harness the body's protein destruction mechanisms. The company's QuEEN platform enables target-centric MGD discovery, supporting its development of MRT-2359, an orally bioavailable MGD targeting GSPT1 for MYC-driven tumors like metastatic non-small cell lung cancer and small cell lung cancer. Clinical development focuses on oncology applications, leveraging biological and genetic rationale for novel therapies. The firm targets oncology segments with MGD-based treatments for specific cancer types. MRT-2359 is the primary product candidate in clinical development, designed to degrade GSPT1 in tumors driven by MYC overexpression. The company's approach centers on rational design of MGDs using its QuEEN platform, aiming to address unmet needs in oncology. Therapeutic applications include metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors, where current treatment options are limited. The focus remains on developing targeted therapies for these specific cancer segments. The company's revenue model relies on advancing MRT-2359 through clinical trials toward regulatory approval. Once approved, it would commercialize MRT-2359 for oncology indications, generating revenue from pharmaceutical sales. The target market includes patients with MYC-driven tumors requiring new treatment options, with potential partnerships for co-development or licensing as the drug progresses. Clinical development stages determine the next phase of revenue generation, with no current products on the market. Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Monte Rosa Therapeutics's Profit Margins

The profit margins of Monte Rosa Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Monte Rosa Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Monte Rosa Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Monte Rosa Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Monte Rosa Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Monte Rosa Therapeutics stock

Net Income of Monte Rosa Therapeutics is -38.63 M USD in 2025.

Net Income of Monte Rosa Therapeutics changed from -72.70 M USD to -38.63 M USD, representing a -46.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Monte Rosa Therapeutics historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Monte Rosa Therapeutics

All Key Metrics — Monte Rosa Therapeutics